Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Chief Financial Officer | February 14, 2025 | February 19, 2025 |
| Notable Labs, Ltd.VBLT · Entity 87239 | Director | January 01, 2023 | January 04, 2023 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | June 26, 2026 | June 30, 2026 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Chief Financial Officer | January 08, 2026 | January 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 249,824 |
Reported balance
After 2025-02-14 transaction · row 1
1 source rowRow 1 · 2025-02-14 · Grant · Acquired 90,100 · Balance 249,824 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2035-02-14 | Direct | 365,800 |
Reported balance
After 2025-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-14 · Grant · Acquired 365,800 · Balance 365,800 F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Notable Labs, Ltd.
Report date January 01, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2038-01-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2038-12-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2039-12-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2040-12-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F5: These options were granted on 01/02/22 under the 2014 Plan and vest over three years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
F5: These options were granted on 01/02/22 under the 2014 Plan and vest over three years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
SCYNEXIS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,522 |
Reported balance
After 2026-06-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 2,875 · Balance 11,522 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2036-06-25 | Direct | 2,875 |
Reported balance
After 2026-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-26 · Grant · Acquired 2,875 · Balance 2,875 F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
Trevi Therapeutics, Inc.
Report date January 08, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2036-01-07 | Direct | 375,000 |
Reported balance
After 2026-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 375,000 · Balance 375,000 F1: This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Entasis Therapeutics Holdings Inc.
Report date July 07, 2022 · Filed July 11, 2022
Section 16 reporting ended · disclosed 2022-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-07-07 · Other · Disposed 22,000 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Other · Disposed 26,583 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-11 · Other · Disposed 11,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.
Unilife Corp
Report date January 26, 2017 · Filed January 30, 2017
Section 16 reporting ended · disclosed 2017-01-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.53 · Expires 2027-01-26 | Direct | 150,000 |
Reported balance
After 2017-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-26 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:04 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001237401-26-000002 · ownership.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,875 Underlying: Common Stock · 2,875 shares Expires 2036-06-25 F3 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:04 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 2,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001237401-26-000002 · ownership.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,522 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2 · balance_after: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:05 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0001193125-26-010361 · ownership.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:16 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000950170-25-091589 · ownership.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-25 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:16 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091589 · ownership.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,183 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 23:25 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 365,800 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001447028-25-000050 · wk-form4_1740007524.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,800 Underlying: Common Shares · 365,800 shares Expires 2035-02-14 F2 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 23:25 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 90,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-25-000050 · wk-form4_1740007524.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,824 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:02 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Shares | 22,183 | $3.28 | $72,826.79 |
DisclosureSEC source: 0001447028-25-000040 · wk-form4_1738789366.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,724 F1 · kind: Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:10 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-24-076239 · ownership.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-19 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:10 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076239 · ownership.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,183 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Shares | 9,593 | $2.31 | $22,183.81 |
DisclosureSEC source: 0001447028-24-000027 · wk-form4_1707180869.xml · nonDerivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,907 F2 · kind: Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001447028-24-000027 · wk-form4_1707180869.xml · derivative · entry 3 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Shares · 450,000 shares Expires 2034-02-01 F3 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F4 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-24-000027 · wk-form4_1707180869.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-029046 · ownership.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 23, 2023 20:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029609 · ownership.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,183 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:11 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 316,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001447028-23-000009 · wf-form4_167545863617086.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,000 Underlying: Common Shares · 316,000 shares Expires 2033-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:11 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-23-000009 · wf-form4_167545863617086.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-22-078789 · tm2220760-3_4seq1.xml · derivative · entry 4 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 26,583 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-22-078789 · tm2220760-3_4seq1.xml · derivative · entry 3 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,583 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerCommon Stock | 27,500 | $2.20 | $60,500.00 |
DisclosureSEC source: 0001104659-22-078789 · tm2220760-3_4seq1.xml · nonDerivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. F2 · price: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherCommon Stock | 22,000 | $2.20 | $48,400.00 |
DisclosureSEC source: 0001104659-22-078789 · tm2220760-3_4seq1.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). F1 · price: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001209191-22-038666 · doc4.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038666 · doc4.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,183 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 22:55 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 285,000 | $2.81 Strike: $2.81 | $800,850.00 |
DisclosureSEC source: 0001447028-22-000011 · wf-form4_164271929611191.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Shares · 285,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005412 · tm223320-3_4seq1.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · shares: This award vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service as a director of the Company. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 5,769 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 6 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,769 Underlying: Common Stock · 5,769 shares Expires 2031-07-15 F8 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F9 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 5 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2029-06-18 F8 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F7 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,538 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 4 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-07-15 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F6 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $5.66 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 3 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-01-17 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F4 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in full on January 1, 2020, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 9,276 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,276 Underlying: Common Stock · 9,276 shares Expires 2031-07-15 F3 · price: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. F3 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,060 | Not disclosed Strike: $6.85 | Not disclosed |
DisclosureSEC source: 0001104659-22-023768 · tm226724-2_4seq1.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,060 shares Expires 2028-04-30 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,060 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 9,276 shares of issuer's common stock, having an exercise price of $2.44 per share. F1 · derivative.exercise_date: The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on May 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 12:31 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001209191-21-041824 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:33 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-045912 · tm2111994-1_4seq1.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:06 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000012 · wf-form4_161359955145004.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:11 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-041739 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| July 06, 2020 Filed Mar 31, 2021 20:04 UTC Amendment | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-023761 · doc4a.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 10, 2020 Filed Oct 6, 2020 20:32 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-20-112660 · a4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:03 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000027 · wf-form4_158211739512646.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001104659-19-037006 · a4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 17:34 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-19-038197 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:04 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000431 · edgar.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Shares · 137,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 21:58 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.66 | $0.00 |
DisclosureSEC source: 0001209191-19-004768 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on January 1, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 13:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-19-001639 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 21:53 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029511 · doc1.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The options vest as follows: 1/3 on 6/11/2019; 1/3 on 6/11/2020; and 1/3 on 6/11/2021. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:52 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 5,325 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-018711 · doc4.xml · derivative · entry 3 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,325 Underlying: Common Stock · 5,325 shares Expires 2023-03-08 F1 · price: Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:52 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 8,875 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-18-018711 · doc4.xml · derivative · entry 2 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,875 Underlying: Common Stock · 8,875 shares Expires 2019-03-14 F1 · price: Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:52 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 11,834 | $1.69 | $19,999.46 |
DisclosureSEC source: 0001209191-18-018711 · doc4.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,834 F1 · price: Reflects the purchase on March 8, 2018, of 11,834 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:22 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 19,989 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001209191-18-001740 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989 Underlying: Common Stock · 19,989 shares Expires 2028-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 12:58 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 20,000 | $1.75 | $35,000.00 |
DisclosureSEC source: 0001178253-17-000011 · wf-form4_149813632239136.xml · nonDerivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 20:45 UTC | Unilife Corp UNIS · Entity 12414 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0000899243-17-002222 · doc4.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.